Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04749433 · ClinicalTrials.gov registry record · Phase 1
Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS
A Phase 1 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT04749433: Clinical Trial Phase 1 study, sponsored by Johns Hopkins University.
NCT04749433 is a Phase 1 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04749433, a Phase 1 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with amyotrophic lateral sclerosis (ALS). The investigators are also interested to see whether use of this radiotracer reveals imaging differences between patients with ALS and healthy patients.
Interventions
- DRUG [11C]CPPC Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04749433
The ClinicalTrials.gov registry entry for NCT04749433 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]CPPC Injection is the first listed.
NCT04749433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04749433 about?
NCT04749433 is a clinical study titled "Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS". The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with amyotrophic lateral sclerosis (ALS). The investigators ar...
What is the current status of trial NCT04749433?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2021-09-01. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT04749433?
The interventions under investigation include: [11C]CPPC Injection (DRUG).
Who is sponsoring clinical trial NCT04749433?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.